Clinical trials: Hepatitis C Viral
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic…
- Trial name
- TOPAZ-I (NCT02219490)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Where
- 187 sites in Algeria, Australia and 25 more
- Volunteers
- 1,596 people
- Sponsor
- AbbVie
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic…
- Trial name
- NCT02461745
- Testing
- ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavirin (RBV) in participants with…
- Trial name
- NCT02536313
- Testing
- SOF/VEL/VOX, RBV
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Gilead Sciences
Hepatitis C
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
The purpose of this study is to determine the decline of virus in the blood and liver in patients treated with telaprevir, pegylated interferon and ribavirin.
- Trial name
- NCT00892697
- Testing
- Telaprevir, Peginterferon alfa-2a, Ribavirin
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Hepatitis C Virus
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
In this study, participants on methadone or buprenorphine/naloxone maintenance therapy will be given boceprevir. Blood samples will be taken at specified intervals to find out whether boceprevir affects the pharmacokinetics of…
- Trial name
- NCT01396005
- Testing
- boceprevir, methadone, buprenorphine/naloxone
- Volunteers
- 21 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4…
- Trial name
- NCT02301936
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
The purpose of this study is to provide confirmatory efficacy and safety data of TMC435 as part of a treatment regimen including peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) in patients with genotype 1 Hepatitis C virus…
- Trial name
- NCT01725529
- Testing
- TMC435, Peginterferon-alpha (PegIFNα-2a), Ribavirin (RBV)
- Where
- 21 sites in China, South Korea
- Volunteers
- 457 people
- Sponsor
- Janssen R&D Ireland
Kidney Transplant, Hepatitis C
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection
- Conditions
- Kidney Transplant, Hepatitis C, HCV
- Trial name
- NCT03801707
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Ohio State University
Chronic Hepatitis C
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
- Trial name
- NCT00983957
- Testing
- BMS-790052, Ortho Tri-Cyclen®
- Where
- 3 sites in United States, Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
The purpose of this study was to evaluate the efficacy, safety and pharmacokinetics of ABT-450/r when given together with ABT-267 and with and without RBV in treatment-naïve participants with genotype 1, 2 or 3 chronic HCV…
- Trial name
- Navigator (NCT01458535)
- Testing
- ABT-450, ABT-267, ribavirin
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatocellular Cancer
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
This research study is a Phase IV clinical trial. Phase IV trials are used to further test and monitor the safety of a drug approved by the FDA and to see if the drug has any other indications that can be used to treat different…
- Trial name
- NCT01849588
- Testing
- Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as…
- Trial name
- PEARL-IV (NCT01833533)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 305 people
- Sponsor
- AbbVie
Chronic Hepatitis C
The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection
The primary objective of this study is to evaluate the effectiveness of TCM-700C as an add-on treatment to the combination drug therapy (Peginterferon α-2b plus Ribavirin) for patients with genotype 1 chronic hepatitis C…
- Trial name
- TCM-700C (NCT00556504)
- Testing
- TCM-700C, Peginterferon alfa-2a, Ribavirin
- Where
- Taiwan
- Volunteers
- 84 people
- Sponsor
- TCM Biotech International Corp.
Hepatitis C
Hepatitis C-Video vs. Brochure Education Delivery
The purpose of this study is to determine the most effective way to give patients information regarding hepatitis C virus infection.
- Trial name
- NCT04204447
- Testing
- Hepatitis C Educational Brochure, Hepatitis C Educational Video
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- State University of New York at Buffalo
Hepatitis C, Chronic, Hepatitis C
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
The objective of the study is to evaluate the costs associated with peginterferon alfa-2b (PegIntron) plus ribavirin (Rebetol) treatment for chronic hepatitis C in the Czech Republic.
- Trial name
- NCT00723632
- Testing
- peginterferon alfa-2b, ribavirin
- Volunteers
- 901 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
A Study to assess the general safety and tolerability of the administration of a 3-dose prime/boost regimen of the MRKAd5 HIV-1 gag vaccine (V520) in subjects with chronic hepatitis C virus infection.
- Trial name
- NCT00857311
- Testing
- MRKAd5 HIV-1 gag vaccine (V520), Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response (RVR) i.e., undetectable hepatitis C virus…
- Trial name
- NCT00704184
- Testing
- Comparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
This is a randomized, multi-site, placebo-controlled trial of a fixed dose combination (FDC) of grazoprevir (MK-5172) 100 mg + elbasvir (MK-8742) 50 mg in participants with chronic Hepatitis C Virus (HCV) genotype (GT) 1, GT4 or…
- Trial name
- NCT02252016
- Testing
- Grazoprevir + Elbasvir
- Volunteers
- 159 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.
- Trial name
- ASTRAL-5 (NCT02480712)
- Testing
- SOF/VEL
- Where
- 15 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences